Personal CFO Solutions LLC Acquires 875 Shares of Eli Lilly and Company (NYSE:LLY)

Personal CFO Solutions LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 26.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,177 shares of the company's stock after acquiring an additional 875 shares during the quarter. Eli Lilly and Company makes up approximately 0.7% of Personal CFO Solutions LLC's portfolio, making the stock its 21st largest holding. Personal CFO Solutions LLC's holdings in Eli Lilly and Company were worth $3,450,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. WestEnd Advisors LLC grew its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Citizens National Bank Trust Department grew its stake in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $43,000. O Brien Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the last quarter. Finally, Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $48,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $777.92 on Wednesday. The stock has a 50-day moving average price of $769.37 and a 200 day moving average price of $800.14. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The firm has a market cap of $737.27 billion, a price-to-earnings ratio of 63.30, a PEG ratio of 1.13 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.58 earnings per share. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. Guggenheim restated a "buy" rating and issued a $936.00 price objective on shares of Eli Lilly and Company in a research note on Friday, June 20th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.